Septic AKI in ICU patients. diagnosis, pathophysiology, and treatment type, dosing, and timing: a comprehensive review of recent and future developments

• Published in: Annals of intensive care Vol. 1; no. 1; p. 32
• Main Authors: Honore, Patrick M, Jacobs, Rita, Joannes-Boyau, Olivier, De Regt, Jouke, Boer, Willem, De Waele, Elisabeth, Collin, Vincent, Spapen, Herbert D
• Format: Journal Article
• Language: English
• Published: Paris Springer Paris 09.08.2011; Springer Nature B.V; BioMed Central Ltd; Springer
• Subjects: Anesthesiology; Critical Care Medicine; Emergency Medicine; Intensive; Intensive care; Medicine; Medicine & Public Health; Review; Dosing; SIRS; Acute Kidney Injury; Pathphysiology; Hemofiltration; Sepsis; Dialysis; Septic Acute Kidney Injury; Timing; Diagnosis; Review; CRRT
• ISSN: 2110-5820; 2110-5820
• DOI: 10.1186/2110-5820-1-32

Evidence is accumulating showing that septic acute kidney injury (AKI) is different from non-septic AKI. Specifically, a large body of research points to apoptotic processes underlying septic AKI. Unravelling the complex and intertwined apoptotic and immuno-inflammatory pathways at the cellular level will undoubtedly create new and exciting perspectives for the future development (e.g., caspase inhibition) or refinement (specific vasopressor use) of therapeutic strategies. Shock complicating sepsis may cause more AKI but also will render treatment of this condition in an hemodynamically unstable patient more difficult. Expert opinion, along with the aggregated results of two recent large randomized trials, favors continuous renal replacement therapy (CRRT) as preferential treatment for septic AKI (hemodynamically unstable). It is suggested that this approach might decrease the need for subsequent chronic dialysis. Large-scale introduction of citrate as an anticoagulant most likely will change CRRT management in intensive care units (ICU), because it not only significantly increases filter lifespan but also better preserves filter porosity. A possible role of citrate in reducing mortality and morbidity, mainly in surgical ICU patients, remains to be proven. Also, citrate administration in the predilution mode appears to be safe and exempt of relevant side effects, yet still requires rigorous monitoring. Current consensus exists about using a CRRT dose of 25 ml/kg/h in non-septic AKI. However, because patients should not be undertreated, this implies that doses as high as 30 to 35 ml/kg/h must be prescribed to account for eventual treatment interruptions. Awaiting results from large, ongoing trials, 35 ml/kg/h should remain the standard dose in septic AKI, particularly when shock is present. To date, exact timing of CRRT is not well defined. A widely accepted composite definition of timing is needed before an appropriate study challenging this major issue can be launched.